The patient's Trifecta GT heart valve had to be replaced after just six years, an experience he says resulted in "permanent injuries." Abbott pulled the devices off the U.S. market in 2023 due to a known risk of structural valve deterioration.
Researchers tracked data from more than 1,000 real-world patients, focusing on 30-day safety and efficacy outcomes. The group shared its findings at TCT 2025 in San Francisco.
